mgm2020 • 13 hours ago Flag
7users liked this postsusers disliked this posts2Reply
Has everyone watched the Cramer video regarding speculative developmental bios???
WATCH IT!! He says that NOW is the time to buy speculative developmental-stage biotechs with good pipelines and "shots on goal" because "economic chaos does not apply to unmet medical needs." He also says that the smaller companies tend to be acquisition targets of big pharma whose pipelines and IP are becoming exhausted. And---he says that these companies tend to trade higher leading into approvals. He spotlighted 3 companies. Receptos and Alder are 2 of them. NEITHER have an approved product yet---they are ALL either in trials or have preclinical data. Alder has gone from $10 to $50 in 12 months and only has 2 drug candidates in trials as well as additional preclinical data supporting other candidates. Receptos has gone from $13 to $200 in 24 months with NO APPROVED DRUGS and they are advancing candidates in autoimmune, anti-inflammatory-----and Crohn's disease and ulcerative colitis---SOUND FAMILIAR?? He says that JUST their drugs for those 2 conditions could be worth $2 BILLION. Currently Receptos has a market cap of $5.5 BILLION with NO approved drug and only 1 compound in phase 3---for MS. And Receptos LOST $1.29/share last quarter!!! But these are the types of developmental biotechs that investors are willing to pay for----and the stocks that earn the high valuations. IDRA WILL BECOME one of these companies. It has the science, it has the leadership, it has the PIPELINE, it has a more advanced GSO than ISIS, they are going after orphan diseases AND unmet medical need, and it has the TIME! I am sure that most shareholders that were in Receptos 24 months ago at $13 would have been ridiculed if they would have predicted a $200 stock price in 24 months! Same with Alder going from $10 to $50 in 12 months---but it DID happen.